Value through Innovation27 July 2016

What is a lay summary?

Lay Summaries and Lay Summary Videos

  • Volasertib - Neoplasms , Leukemia
    Clinical Study Number 1230.27
    Study Indication Neoplasms ; Leukemia
    Product Volasertib
    Generic Name Volasertib
    Lab Code BI 6727
    Clinical Phase I
    Study Title

    Open, non-controlled, dose-escalating Phase I trial to evaluate the pharmacokinetics, pharmacodynamics, tolerability, and toxicity of volasertib in paediatric patients from 2 years to less than 18 years of age with acute leukaemia or advanced solid tumour, for whom no effective treatment is known

    Study Document
    Lay summary 1230.27 english
  • BI 860585 - Neoplasms
    Clinical Study Number 1325.1
    Study Indication Neoplasms
    Product BI 860585
    Generic Name BI 860585
    Lab Code BI 860585
    Clinical Phase I
    Study Title

    An open-label, Phase I, dose-finding study of BI 860585 administered orally in a continuous dosing schedule as a single agent and in combination with exemestane or with paclitaxel in patients with various advanced and/or metastatic solid tumours

    Study Document
    Lay summary 1325.1 english